(Yicai Global) Dec. 22 -- Staidson Beijing Biopharmaceuticals said it will share 10 percent of future net sales of a new Covid-19 treatment with the antibody developer, Germany's InflaRx.

Staidson is preparing to register an application in China for the BDB-001 injection, a monoclonal antibody drug that the pair has been jointly developing, the Beijing-based firm said in a statement yesterday, without disclosing the predicted timeline for approval.

Shares of InflaRx [NASDAQ: IFRX] soared 26 percent to USD2.70 in New York yesterday, though the stock fell back a little in pre-market trading today.

The drug is designed to reduce inflammation in people with serious Covid-19 symptoms. It has gone through clinical trials in India, Indonesia, Bangladesh, and other countries since February 2020. InflaRx has agreed to provide some technical data for the registration.

Staidson [SHE: 300204] closed 1.5 percent lower at CNY18.21 (USD2.60) in Shenzhen today, after hitting the highest intraday price since April.

Jena-based InflaRx began working with Staidson in 2015.

Editor: Emmi Laine, Xiao Yi